Ferring commits $10 million to March of Dimes to expand research needed to end preterm birth
Ferring announces exclusive agreement with Alrise Biosystems for the development of an injectable, controlled-release peptide
Ferring highlights progress on social and environmental goals in Corporate Social Responsibility (CSR) Review 2015-2016
Ferring appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer
Ferring International Center S.A.Ch. de la Vergognausaz 50CH-1162 Saint-PrexSwitzerlandTel: +41 58 301 00 00Fax: +41 58 301 00 10
Email for media enquiries only.For other queries, please see our Contact page.
Ferring International Center S.A.Ch. de la Vergognausaz 50 1162 Saint-PrexSwitzerland
Tel: +41 58 301 00 00Fax: +41 58 301 00 10
This global corporate website provides general information about the global Ferring Group. For information about Ferring or its products in a specific country, please select your country in the Global Locator. FERRING, the FERRING PHARMACEUTICALS logo and other Ferring product trade names are trademarks of Ferring B.V. save where indicated otherwise. ©2017 Ferring B.V.